International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

"Therapeutic Appliccations of Crispr – Cas 9: Current Prospects and Challenges."

Sova.A. Sasmal.,Dr.Yogesh B. Raut, Dr.Sanjay K. Bais
Fabtech College Of Pharmacy, Sangola-413307, India

Date of Submission: 05-12-2025 Date of Acceptance: 12-12-2025

ABSTRACT:
CRISPR technology is rapidly grow to be among the most influential instruments in contemporary biotechnology, offering the ability to accurately modify faulty genes and repair harmful mutations.Due to its exceptional precision, operational efficiency, and broad applicability, it is regarded as it has become a highly promising option for future therapeutic applications.To address the wide range of genetic alterations seen in different diseases, researchers have created numerous improved Cas9 variants and engineered systems.
However, one of the biggest obstacles still faced today centre around ensuring proper and secure conveyance elements directly in affected cells present in the body, as a completely reliable in an optimal in vivo delivery platform is still lacking to be developed. Moving forward, scientific efforts are expected to concentrate on advanced non-viral delivery systems with better targeting functions. It is also anticipated that unique physiological or pathological markers of each disease could eventually guide more accurate gene-editing and delivery approaches.
KEYWORDS: Molecular biology, medicine, genome editing, and molecular genetics.

I. INTRODUCTION

The CRISPR-Cas9 method is dramatically reshaped modern DNA edit research through providing a method that is both exact and efficient to modify DNA sequences. Once directed Cas9 produces a double-strand break at the right location, after which the self-repair of the cell machinery introduces the desired genetic change.Given its ease of operation, economic feasibility, and high precision, it has rapidly positioned itself and foremost technologies in modern biotechnology most powerful tools in geneticengineering[1,2].

The intentional alteration of DNA is "genome editing." within living cells, including the addition, removal, or alteration of targeted genetic segments.It refers to a notable DNA arrangement where short palindromic repeats appear at regular intervals, each separated by different spacer sequences. This arrangement functions, a microbial immunological process that adapts, enabling prokaryotes to be recognize and guard against invading viruses or bacteriophages through CRISPR-associated proteins such as Cas9[13].

❖ COMPONENTS :

The CRISPR/Cas framework is divided into two primaryclasses distinguished by how their Cas proteins are built and what roles they perform. Class I variants use multi-component protein assemblies.while Class II categories depend on one flexible Cas enzyme.In particular, the Type II mechanism has emerged as the most generallyexplored and used in a geneticengineering due to its simple architecture and strong overall efficiency.At its core technology depends on two primary elements: the DNA-cutting enzyme and its guiding RNA.The Cas9 nuclease, first discovered in Streptococcus pyogenes, served as the initial Cas protein modified for genome editing. This large, 1,368-amino-acid protein acts as a molecular scissor, Making an accurate rupture at the intended DNA location. Structurally, Cas9 contains two major lobes:the recognition domain and the realm of Nucleus.This each domain break a different strand, and PAM-binding site is crucial for detecting the correct target sequence and initiating DNA attachment[4].This element contain 2 natural molecules.Within the crRNA, an 18–20 nucleotide stretch hybridizes with the complementary DNA site, whereas the tracrRNA folds into loops that contact Cas9and help stabilize the entire complex.This sgRNA can be custom-designed to bind nearly any genomic region that lies adjacent to a PAM motif, making the system remarkably flexible for carrying out gene editing.Together, the Cas9 enzyme and the guide RNA create a programmable system capable of modifying genes with remarkable precision.Its minimal complexity and high adaptability have driven its rapid acceptance in various areas of science made

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

CRISPR-Cas9 one of the most important technologies in today's genetic engineering field.



Fig 1: Constituent parts.

FLOW CHART :

gRNA + Cas9 enzyme → sgRNA

↓

attaches itself to the DNA

↓

Double-strand break ✂

↓

DNA repair (NHEJ / HDR)

❖ **DISCOVERY AND DEVELOPMENT :**

The adaptability, efficiency, and simplicity of CRISPR-Cas9 have fundamentally transformed the landscape of modern genome editing. A major breakthrough came when Jennifer Doudnaand Emmanuelle Charpentier presented CRISPR-Cas9 as a customizable gene-editing system gene-editing tool, publishing their landmark findings in Science in 2014. Their work demonstrated that a synthetic solitary guide could accurately guide to cleave certain lines of DNA in vitro, establishing the foundation for rapid technological advancement in the field.Continuous research has expanded its utility, leading to improvements in precision, efficiency, and versatility [5]. One of the first clear proofs of its scientific promise came from the successful editing of human cell genomes with CRISPR-Cas9, highlighting itspractical relevance for biomedical investigations.A major focus of subsequent development has been improving the specificity of Cas9 to minimize unintended, off-target DNA cuts. Multiple approaches have been explored to improve precision.This advancement highlighted feasibility of modifying Cas9 itself to achieve higher precision and safer gene-editing outcome[6].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494



Fig 2: CRISPR Development History.

- EARLY DETECTION USING CRISPR TECHNOLOGY**:**

In 1987, Nakata and colleagues, while analyzing the gene of Escherichia coli, identified an unusual sequence located near the gene's 3′ terminal region.

A comprehensive description of these distinctive repeat sequences was published in 2002 by Jansen and co-workers, who introduced the term CRISPR classify this family,genetic elements. Identified multiple proteins, including Cas1 through Cas4, which were recognized as essential components of the CRISPR defense mechanism.



Fig 3: Schematic depiction of tools for cleaving DNA strands.
a)Cas9 creates flat ends by cleaving DNA double strands.b)The single DNA strand is cleaved by Cas9 nickase (Cas9n)c) Cas12a creates sticky cuts DNA double strand.d)RNA strands are recognized and cleaved by Cas13a.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

SUMARRY TABLE :

Cas protein	Target	Cut type	PAM/PFS	Ends produced	Key applications
Cas9	DNA	Double strand break	NGG	Blunt	Genome editing ,gene knockout
Cas9n	DNA	Single strand break	NGG	Nick	Precision edit
Cas12a	DNA	Double strand break	TTTV	Sticky	Gene insertion , diagnostics
Cas13a	RNA	SsRNA Cleavage	PFS	N/A	RNAinterference , viral diagnostics

- **Key Cas Nuclease Mechanisms**:

A. Nickase Cas9 (Cas9n):
Cas9n is mutant.kind of Cas9 with a single nuclease domain (RuvC or HNH) rendered inactive.
With more specificity and less off-target effects, staggered double-strand cuts can be produced by two Cas9n–sgRNA complexes that target opposing strands.

B. Cas12a, originally termed Cpf1:
Origin: Acidaminococcus sp. Or Lachnospiraceae bacteria.
Identifies a 5′-TTTV-3′ T-rich PAM sequence.
Produces staggered (sticky) ends from DNA cleavage, as opposed to blunt ends like Cas9.
It is a more compact and straightforward editing approach because it only needs one crRNA (no tracrRNA).
Besides its primary activity, Cas12a can cleave collateral ssDNA. that is helpful for diagnostic tests (like DETECTR).

C. Cas13a:
prefers to target RNA molecules over DNA.
CrRNA directs Cas13aand binds to certain RNA sequences before activating and cleaving the target and neighbouring RNAs (collateral cleavage).
does not identify a PAM, but rather a protospacer flanking site (PFS).
widely used in diagnostic tests (like SHERLOCK) and RNA knockdown[19].

❖ **MECHANISM:**

The CRISPR gene-editing mechanism operates through three majorsteps: target identification, DNA strand cleavage, and subsequent repair. A synthetic single-guide RNA first identifies the specific DNA sequence to be edited by base-pairing with its complementary region, derived from the crRNA portion of the guide.

This exact PAM sequence varies among microbes but typically ranges from two to five nucleotides. Upon locating this motif, Cas9 triggers targeted DNA helix separation, allowing the RNA specific for hybridize with the corresponding strand. Although this precise molecular process of DNA melting is not fully understood, this step is essential for target engagement.Once the RNA–DNA hybrid is formed, Cas9 becomes catalytically active. After cleavage, the broken DNA is heal through the inherenthealing processes, which ultimately determine the outcome of the editing event[7].

❖ **HOW CRISPR CAS – 9 WORK :**



Fig 4: HOW CRISPR WORKS

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

The CRISPR-Cas9 gene-editing process occurs in three fundamental steps: (1) target recognition, (2) DNA cleaving, and (3) healing. A specifically designed The guide RNA leads Cas9 of its DNA target nuclease targeting the exact genomic sequence that needs to be modified.After recognizing thesequence, Cas9 cleaves both strands to the site. To accomplish this, Cas9 first promotes local DNA unwinding, allowing the guide RNA , align with the opposite DNA strand, creating structure.

This interaction activates Cas9, enabling it to split the DNA molecule.HNH mediates cleavage of the DNA strand to the guide RNA, whereas RuvC cleaves the opposing strand, forming a break.The break is subsequently repaired by internal repair machinery.[8] .

Cells respond to Cas9-induced DSBs using two primary repair strategies: NHEJ and HDR, with NHEJ being the default in the absence of donor DNA.This reconnects the broken DNA ends but this process usually introduces small cut and break, which may result in genome disruption. In contrast, the functions as a more accurate repair pathway and requires If a foreign DNA template with matching sequences is provided sequences surrounding the break. This template allows for precise gene correction, replacement, or insertion, making HDR especially valuable for therapeutic genome editing.By understanding the role of a target gene and the underlying disease mechanism, researchers can harness the cycle of Cas9-mediated cleavage followed by NHEJ or HDR to achieve controlled gene disruption, modification, or replacement. This ability forms the foundation of CRISPR-Cas9–based therapeutic strategies[9].



Fig 5: CRISPR-Cas9's Mechanism

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

II. APPLICATIONS :

Researchers anticipate that Refinements in approach will create new avenues for addressing genetic disorders, enhancing the wholesome value in plants and combating infectious diseases. In recent years, numerous applications and clinical studies involving CRISPR/Cas9 have emerged, highlighting its rapidly expanding influence.Even as a newly discovered entity, the technology has already demonstrated remarkable potential across multiple sectors, biotechnology, medicines.



Fig 6: APPLICATIONS

1) CRISPR CAS 9 TECHNOLOGY APPLICATION IN AGRICULTURE :

It could dramatically impact farming by providing the means to highly argeted genome editing in crops and farm animals. Its applications in agriculture have expanded rapidly, aiming to enhance crop output and strengthen resistance to environmental stressors, and ensure global food security[10].

A central purpose of using Genome editing to advance plant quality and yield. This demonstrates how targeted genetic alteration can quickly and effectively strengthen crop resilience.Cas9 helps speed up plant breeding, unlike traditional methods that often need many generations to develop favorable traits. In contrast, CRISPR enables direct, precise edits in germline cells, dramatically reducing breeding time. By fine-tuning key genetic regulators—such as those controlling grain size—researchers can rapidly engineer improved crop varieties[11].



Fig 7:Gene editing.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

2**) MEDICINES :**

CRISPR-Cas9 has established itself as a game-changing technology in modern medicine due to its ability to alter genes in a targeted and accurate manner. One of its most important medical applications is in the investigation of gene function and mechanisms of disease. By selectively modifying or disabling specific genes in human cells or model organisms, scientists enables understanding of the impact of these genes on health and illness. Large-scale CRISPR screening studies—such as the genome-wide knockout experiments performed by Shalem and colleagues—have helped identify numerous genes essential for cancer cell growth and survival[12]. This technology makes it possible to correct harmful mutations directly within a patient's cells. For example, researchers have successfully repaired disease-causing mutations associated with β-thalassemia in stem cells derived from affected individuals. Such breakthroughs highlight the potential of CRISPR-Cas9 to provide long-lasting cures for inherited disorders rather than merely managing symptoms.Beyond treatment, CRISPR-Cas9 is also being explored for advanced diagnostics, personalized medicine, and regenerative therapies. Its precision enables the development of highly sensitive detection systems for infectious and genetic diseases[13].

In summary, CRISPR-Cas9 holds vast promise in medicine. It enhances our understanding of disease biology, supports the creation of accurate diagnostic tools, and enables the design of precise gene therapies. With continued progress, CRISPR-Cas9 is poised to transform how genetic disorders are detected, treated, and potentially cured

3**.Medical and clinical studies involving Cas9 technology :**

"Developing interventions that fix or adjust genetic abnormalities is a major focus of clinical science." One of its most promising applications involves directly repairing disease-causing mutations within patient-derived cells or tissues. This landmark achievement highlighted the feasibility of using CRISPR-based strategies to treat infectious diseases through Alteration of genes.Scientists are leveraging CRISPR-Cas9 to create new approaches for combating cancer. Researchers are investigating methods to selectively target and destroy malignant cells by editing genes that are uniquely altered in cancers .Evidence suggests that CRISPR-Cas9 has the capacity to be designed to eliminate cells carrying specificleukemia-associated fusion genes, offering a targeted approach, it selectively cuts the DNA double strand.Another major advancement in clinical science is the growth of ex vivo gene therapy using CRISPR-Cas9.This technique involves removing a patient's cells, editing their genes outside the body, and then reinfused to perform therapeutic functions. By modifying T cells from patients with advanced malignancies using CRISPR-Cas9, scientists improved their ability to attack cancer into cells, facilitating the progress of next-generation immunotherapy strategies[14].

Although progress has been made, various challenges remain that require attention resolved before CRISPR-Cas9 can be extensively utilized in medical procedures. Potential issues include off-target gene edits, ensuring the controlled and effective insertion of CRISPR components into human tissues, evaluating long-term safety, and addressing the concerns about morality, especially when it comes to altering genes passed to future generations. Rigorous regulation and continued research are essential aimed at confirming that interventions using CRISPR protect safety while respecting ethical principles.

4)**CRISPR CAS 9 TECHNOLOGY Biotech Uses and Applications :**

Its simplicity haveset the stage for progress in manipulating genomes, regulating genes, metabolic engineering, and innovations in synthetic biology. This system allows accurate modification of DNA sequences spanning bacteria, yeast, plant species, and mammals. Such targeted editing has made it much easier to develop genetically modified organisms (GMOs) that possess improved traits or entirely new biological capabilities.A key demonstration of CRISPR's potential is the successful engineering of yeast strains optimized for producing valuable metabolites. By fine-tuning specific genes, enhance pathways involved in he fabrication of medical drugs, alternative fuels, and industrial-grade chemicals, making production more efficient and cost-effective.

CRISPR-Cas9 has also greatly advanced the creation of animal systems utilized for understanding human disease. Traditional genetic engineering methods required long time frames and complex procedures. In contrast, CRISPR enables the rapid introduction of precise mutations that mimic human genetic disorders. These models are essential for exploring disease mechanisms, testing new therapies, and understanding gene function at a more advanced level[15].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

Overall, CRISPR-Cas9 continues to reshape biotechnology by making genetic manipulation faster, more accurate, and more accessible. Its contributions to metabolic engineering, organism improvement, and disease modelling highlight its vast potential for future biotechnological innovations.

5)CRISPR CAS 9 TECHNOLOGY APPLICATION IN BIOINFORMATIES:

One major area where bioinformatics and machine learning contribute is predicting off-target effects. By analyse genomic sequences with algorithms trained Leveraging large amounts of data, these prediction methods aid researchers in design more accurate guide RNAs and minimize unwanted edits. Machine learning plays a key role in examining extensive data produced during CRISPR-based screening experiments. In such screens, thousands of genes may be edited simultaneously to determine their impact on cell behavior or disease pathways. Bioinformatics pipelines, including methods like neural networksmethods including random forests and SVMs are utilized for processing and interpreting these sophisticated datasets. These tools help identify essential genes, uncover gene–gene interactions, and reveal biological pathways linked to specific phenotypes.

This enables rapid interpretation of large datasets, more reliable predictions, and the detection of genetic insights not easily observable through lab experiments[16].

6) **THERAPEUTIC ROLE :**

The first human trial using a CRISPR-based therapy was carried out in patients with treatment-resistant lung cancer. Significantly, patients experienced no major complications from the therapy and the engineered T-cells remained detectable in the patients' bodies for up to nine Shows long-term safety and persistence post-infusion. CRISPR is also under investigation for a promising tool for treating infectious diseases, particularly bacterial and viral infections. One significant research focus is HIV/AIDS. In 2017, researchers at Temple University demonstrated that the technology could prevent HIV-1 replication and excise the virus's DNA from infected cells in animal models. Beyond directly cutting the HIV genome, CRISPR can also prevent the virus from entering human cells. This is achieved by editing the CCR5 gene, which encodes a receptor required for HIV entry. Supporting this, an in-vitro study from China showed that CRISPR-modified CCR5-deficient cells displayed no signs of toxicity and were more resistant to HIV infection compared to unedited cells[17].

❖ **THE POTENTIALOF CRISPR THERAPY DURING THE C-19:**

The rapid development of CRISPR technologies has become especially relevant during the persistent problems posed by novel infectious diseases. Traditional diagnostic approaches, such as molecular assays and antibody-based tests also possess certain limitations. The real-time RT-PCR test designed by the U.S.The CDC is able to detect viral RNA, but results may take several hours to obtain to over a day to process and may produce false-negative results in roughly one-third of cases. Serological tests, while quicker, cannot identify early infections because antibodies typically appear days or weeks after exposure.

In response, researchers developed a CRISPR-Cas12–based diagnostic system known as SARS-CoV-2 DETECTR, which offers approximately 95delivers dependable outcomes in close to 40 minutes. This assay integrates RNA extraction, reverse transcription, and isothermal amplification via RT-LAMP. After amplification, Cas12—guided by a specific RNA sequence—recognizes and cleaves target regions in the SARS-CoV-2 N (nucleoprotein) and E DNA. A negative test produces a single band at the sample loading zone, while one or two upper bands indicate a positive result. A lateral-flow strip allows for a simple, visual readout, making the technique suitable for rapid and accessible testing.

III. LIMITATIONS

One of the main weaknesses of CRISPR-Cas9 is that it may inadvertently cut DNA at non-target sites. However, mismatches at the far (distal) end of the sgRNA often do not cause complete detachment. Instead, the final three to five bases can form an unusual, strained duplex structure. This evolutionary flexibility is thought to help bacteria fight rapidly mutating viruses such as phages[18].

Several analytical methods, including GUIDE-seqthey are used to uncover occurrences. Improving the precision of sgRNA design and engineering Cas9 variants that disengage from mismatched DNA can reduce unintended edits[19,20].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 929-939 www.ijprajournal.com ISSN: 2456-4494

IV. CHALLENGES

Ways to Administer :

This Cas9-based editing system machinery can be delivered into cells through chemical, viral, or physical vectors, eachevery method offers particular pros and associated challenge. For ex vivo therapeutic applications, non-viral approaches—such as chemical and physical delivery—are generally preferred due to their safety and reduced risk of insertional mutagenesis[21].

Physical Delivery Methods:

Different physical approaches has implemented to transfer CRISPR tools into cells:

Electroporation:

This method temporarily disrupts the cell membrane using a high-intensity electric pulse, promoting the effective transport of Cas-9 into the cytoplasm. Despite its high delivery rate, electroporation often results in significant reductions in cell viability, especially in sensitive primary cells[22].

Microinjection:

Microinjection delivers the CRISPR/Cas9 complex directly into individual cells under a microscope. It enables precise gene editing in single cells, yet the technique involves significant effort and calls for specialized skills, and is limited by low throughput and potential mechanical damage to cells[23].

V. FUTURE DIRECTIONS

CRISPR-Cas9 technology has transformed multiple scientific fields, including fields spanning biotechnology, farming, ecology, and medicine. With continuous innovation, the future applications of CRISPR-Cas9 are expanding rapidly, offering great promise for research and therapeutic development. Several emerging directions reflect the next phase of CRISPR-Cas9 advancement[24,25].

One key goal for future research is to strengthen the accuracy and targeted control of genome alterations Scientists are actively working to limit unintended edits and enhance the accuracy prevent unwanted genomic alterations. Approaches under investigation include engineered high-fidelity Cas9 proteins, optimized guide RNA structures, and improved delivery platforms. These improvements aim to make CRISPR-Cas9 improved safety and dependability for therapeutic applications.Another important direction is the expansion using CRISPR for modifications outside of DNA.Efforts are underway to develop CRISPR approaches that target RNA for the purpose of enable precise RNA manipulation. This approach makes use of Cas13 enzymes, which can selectively target and edit RNA molecules without altering the genome. These tools broaden therapeutic possibilities, especially for diseases caused by RNA or point mutations. Studies have already demonstrated successful programmable RNA employing CRISPR/Cas13 to carry out RNA modifications in human cells[26].

VI. CONTROVERSY

CRISPR-Cas9 technology, despite its remarkable promise, has also introduced several ethical, legal, and societal challenges. This subsection highlights the major concerns and ongoing global debates surrounding its use. One of the key contentious points is germline genome editing, in which modifications are made to embryos or reproductive cells, making these changes inheritable. These actions lead to serious debates over the enduring influence on descendants and the uncertainty involved of genetic alterations, and the possibility of enabling the creation of so-called “designer babies.” The international controversy intensified in 2018 after reports emerged of genetically edited twin girls born in China, an event that led to worldwide criticism and renewed demands for strict oversight and clear regulations on germline editing[27].

Even with notable improvements aimed at enhancingaccuracy, the risk of unintended mutations remains a critical issue, as these changes may pose unknown risks impacting human life or the surrounding ecosystem. This has prompted ongoing discussions on establishing comprehensive safety practices, combined with more accurate risk assessment tools, and ensuring transparent reporting of off-target activity[28,29].

CRISPR-Cas9 has also sparked debate in terms of intellectual property and patent rights[30,31]. As multiple institutions and researchers claim ownership over key components of the technology, legal disputes have emerged regarding who holds control, how licensing should be managed, and what impact these decisions may have on scientific progress and global access to CRISPR-based therapies[32].

VII. CONCLUSION

To conclude, this article offered an extensive outlined thisediting tool and explored its

extensive utilizations across multiple fields. Each subsection focused on a specific dimension of the technology, highlighting its role in environmental sciences, fisheries, agriculture, biotechnology, nanotechnology, health, and bioinformatics. Together, these discussions emphasized not only the transformative potential of CRISPR-Cas9 but also the significant notable scientific progress observed in the past several years.

In parallel, the review pointed out the ethical concerns, regulatory challenges, and societal debates associated with using advanced gene-editing approaches. Tackling these challenges is essential for guaranteeing responsible and safe implementation. Overall, this comprehensive examination depends our grasp and underscores its importance in shaping future innovations, guiding continued research, and supporting the conscientious and ethical implementation of this pioneering technology.

REFERANCE

[1]. Bhokisham, N., Laudermilch, E., Traeger, L. L., et al. (2023). CRISPR-Cas system: The current and emerging translational landscape. Cells, 12(8), 1103.

[2]. Meng, H., Nan, M., Li, Y., et al. (2023). Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer.Frontiers in Endocrinology, 14, 1148412.

[3]. Gaj, T., Ss, J., & Liu, J. (2016). Genome-editing technologies: Principles and applications. Cold Spring Harbor Perspectives in Biology, 8, a023754. https://doi.org/10.1101/cshperspect.a023754

[4]. Li, T., Yang, Y., Qi, H., et al. (2023). CRISPR-Cas9 therapeutics: Progress and prospects. Signal Transduction and Targeted Therapy, 8(1), 36.

[5]. Naeem, M., &Alkhnbashi, O. S. (2023). Current bioinformatics tools to optimize CRISPR-Cas9 experiments to reduce off-target effects. International Journal of Molecular Sciences, 24(7), 6261.

[6]. Fu, Y., Sander, J. D., Reyon, D., et al. (2014). Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature Biotechnology, 32(3), 279–284.

[7]. Mei, Y., et al. (2016). Recent progress in CRISPR/Cas9 technology. Journal of Genetics and Genomics, 43(2), 63–75. https://doi.org/10.1016/j.jgg.2016.01.001

[8]. Jiang, F., &Doudna, J. A. (2017). CRISPR-Cas9 structures and mechanisms. Annual Review of Biophysics, 46, 505–529.

[9]. Yang, H., et al. (2020). Methods favoring homology-directed repair choice in response to CRISPR/Cas9-induced double-strand breaks. International Journal of Molecular Sciences, 21, Article 6461.

[10]. Shan, Q., et al. (2013). Targeted genome modification of crop plants using a CRISPR-Cas system. Nature Biotechnology, 31(8), 686–688.

[11]. González, M. N., Massa, G. A., Andersson, M., et al. (2023). CRISPR-Cas9 technology for potato functional genomics and breeding. Methods in Molecular Biology, 2653, 333–361.

[12]. Shalem, O., Sanjana, N. E., & Zhang, F., et al. (2015). High-throughput functional genomics using CRISPR-Cas9. Nature Reviews Genetics, 16(5), 299–311.

[13]. Zhen, S., Hua, L., & Liu, Y. H., et al. (2017). Mutant p53 gain of function in cancer. Cancer Letters, 376(1), 144–153.

[14]. Chadwick, A. C., &Musunuru, K. (2017). Treatment of dyslipidemia using CRISPR/Cas9 genome editing.Current Atherosclerosis Reports, 19(7), 32.

[15]. Guo, M., Zhang, X., & Liu, J., et al. (2020). OsProDH negatively regulates thermotolerance in rice. Rice, 13(1), 1–5.

[16]. Alkhnbashi, O. S., Meier, T., Mitrofanov, A., et al. (2020). CRISPR-Cas bioinformatics. Methods, 172, 3–11.

[17]. Liu, Z., Chen, S., Jin, X., et al. (2017). Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection. Cell & Bioscience, 7(1), Article 17. https://doi.org/10.1186/s13578-017-0174-2

[18]. Zhu, X., et al. (2019). Cryo-EM structures reveal coordinated domain motions that govern DNA cleavage by Cas9. Nature Structural & Molecular Biology, 26, 679–685. https://doi.org/10.1038/s41594-019-0269-z

[19]. Kocak, D. D., et al. (2019). Increasing the specificity of CRISPR systems with engineered RNA secondary structures. Nature Biotechnology, 37, 657–666. https://doi.org/10.1038/s41587-019-0154-8

[20]. Nahmad, A. D., et al. (2022). Frequent aneuploidy in primary human T cells after CRISPR-Cas9 cleavage. Nature Biotechnology, 40, 1807–1813. https://doi.org/10.1038/s41587-022-01415-3

[21]. Zhang, S., Shen, J., Li, D., & Cheng, Y. (2020). Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing.Theranostics, 11(2), 614–648. https://doi.org/10.7150/thno.47007

[22]. Lino, C. A., Harper, J. C., Carney, J. P., &Timlin, J. A. (2018). Delivering CRISPR: A review of the challenges and approaches. Drug Delivery, 25(1), 1234–1257. https://doi.org/10.1080/10717544.2018.1474964

[23]. Shah, A., Aftab, S., Nisar, J., Naeem, M., & Jan, F. (2021). Lipid- and polymer-based nanoparticle systems for the delivery of CRISPR/Cas9.Journal of Drug Delivery Science and Technology, 65, 102728. https://doi.org/10.1016/j.jddst.2021.102426

[24]. Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., et al. (2015). Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature, 523(7561), 481–485.

[25]. Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., et al. (2017). RNA targeting with CRISPR-Cas13. Nature, 550(7675), 280–284.167. Maeder, M. L., Stefanidakis, M., Wilson, C. J., et al. (2019).Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nature Medicine, 25(2), 229–233.

[26]. Shalem, O., Sanjana, N. E., Hartenian, E., et al. (2014). Genome-scale CRISPR-Cas9 knockout screening in human cells. Science, 343(6166), 84–87.

[27]. Greely, H. T. (2019). CRISPR'd babies: Human germline genome editing in the "He Jiankui affair." Journal of Law and the Biosciences, 6(1), 111–183.

[28]. Ayanoğlu, F. B., Elçin, A. E., &Elçin, Y. M. (2020). Bioethical issues in genome editing by CRISPR-Cas9 technology. Turkish Journal of Biology, 44(2), 110–120.

[29]. Nelson, J. P., Selin, C. L., & Scott, C. T. (2021). Toward anticipatory governance of human genome editing: A critical review of scholarly governance discourse. Journal of Responsible Innovation, 8(3), 382–420.

[30]. Mark, J. K. K., Lim, C. S. Y., Nordin, F., et al. (2022). Expression of mammalian proteins for diagnostics and therapeutics: A review. Molecular Biology Reports, 49(11), 10593–10608.

[31]. Chin, D. S., Lim, C. S. Y., Nordin, F., et al. (2022). Antibody-dependent cell-mediated cytotoxicity through natural killer (NK) cells: Unlocking NK cells for future immunotherapy. Current Pharmaceutical Biotechnology, 23(4), 552–578.

[32]. Suwito, B. E., Adji, A. S., Wardani, V. A. K., et al. (2022). A review of CRISPR-Cas9 for ASCVD: Treatment strategies and potential targeting of the PCSK9 gene using CRISPR-Cas9 to prevent atherosclerotic vascular disease. Bali Medical Journal, 11(2), 985–993.